CN105188718A - 晚期糖化终产物(age)前体的螯合剂 - Google Patents

晚期糖化终产物(age)前体的螯合剂 Download PDF

Info

Publication number
CN105188718A
CN105188718A CN201480026330.6A CN201480026330A CN105188718A CN 105188718 A CN105188718 A CN 105188718A CN 201480026330 A CN201480026330 A CN 201480026330A CN 105188718 A CN105188718 A CN 105188718A
Authority
CN
China
Prior art keywords
alkyl
pharmaceutical composition
composition according
group
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026330.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·R·霍姆斯-法利
P·达尔
M·贝塞夫
R·J·米勒
A·T·帕普利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN105188718A publication Critical patent/CN105188718A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201480026330.6A 2013-03-15 2014-03-12 晚期糖化终产物(age)前体的螯合剂 Pending CN105188718A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
US61/792,719 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (1)

Publication Number Publication Date
CN105188718A true CN105188718A (zh) 2015-12-23

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026330.6A Pending CN105188718A (zh) 2013-03-15 2014-03-12 晚期糖化终产物(age)前体的螯合剂

Country Status (24)

Country Link
US (2) US20160024233A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968403A1 (cg-RX-API-DMAC7.html)
JP (4) JP2016512830A (cg-RX-API-DMAC7.html)
KR (1) KR20150130492A (cg-RX-API-DMAC7.html)
CN (1) CN105188718A (cg-RX-API-DMAC7.html)
AR (1) AR095593A1 (cg-RX-API-DMAC7.html)
AU (2) AU2014235500A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023404A8 (cg-RX-API-DMAC7.html)
CA (1) CA2906501A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015002624A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150545A (cg-RX-API-DMAC7.html)
DO (1) DOP2015000221A (cg-RX-API-DMAC7.html)
EA (1) EA201591733A1 (cg-RX-API-DMAC7.html)
HK (1) HK1220607A1 (cg-RX-API-DMAC7.html)
IL (1) IL241406A0 (cg-RX-API-DMAC7.html)
MA (1) MA38487A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015012843A (cg-RX-API-DMAC7.html)
PE (1) PE20151766A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015502019A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201707590XA (cg-RX-API-DMAC7.html)
TN (1) TN2015000390A1 (cg-RX-API-DMAC7.html)
TW (1) TW201521744A (cg-RX-API-DMAC7.html)
UY (1) UY35441A (cg-RX-API-DMAC7.html)
WO (1) WO2014150873A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
MX2020002048A (es) * 2017-08-31 2020-09-21 Cytosorbents Corp Reduccion de productos finales de glicacion avanzada a partir de fluidos corporales.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CN1511039A (zh) * 2001-04-18 2004-07-07 ԭ���ø� 降低血浆葡萄糖的方法
US20050165190A1 (en) * 2003-11-03 2005-07-28 Symyx Therapeutics, Inc. Polyamine polymers
US20070065443A1 (en) * 2004-02-17 2007-03-22 Annette Tobia Fructoseamine 3 kinase and the formation of collagen and elastin
CN101268093A (zh) * 2005-03-31 2008-09-17 法马门斯公司 Age抑制剂
CN102858817A (zh) * 2010-02-24 2013-01-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CN1511039A (zh) * 2001-04-18 2004-07-07 ԭ���ø� 降低血浆葡萄糖的方法
US20050165190A1 (en) * 2003-11-03 2005-07-28 Symyx Therapeutics, Inc. Polyamine polymers
US20070065443A1 (en) * 2004-02-17 2007-03-22 Annette Tobia Fructoseamine 3 kinase and the formation of collagen and elastin
CN101268093A (zh) * 2005-03-31 2008-09-17 法马门斯公司 Age抑制剂
CN102858817A (zh) * 2010-02-24 2013-01-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A. GUGLIUCCI等: "The polyamines spermine and spermidine protect proteins from structural and functional damage by AGE precursors a new role for old molecules", 《LIFE SCIENCES》 *

Also Published As

Publication number Publication date
JP2022037143A (ja) 2022-03-08
IL241406A0 (en) 2015-11-30
CA2906501A1 (en) 2014-09-25
PH12015502019A1 (en) 2016-01-11
HK1220607A1 (zh) 2017-05-12
BR112015023404A8 (pt) 2019-12-03
WO2014150873A1 (en) 2014-09-25
AR095593A1 (es) 2015-10-28
EA201591733A1 (ru) 2016-01-29
JP2020055850A (ja) 2020-04-09
AU2014235500A1 (en) 2015-11-05
EP2968403A1 (en) 2016-01-20
US20160024233A1 (en) 2016-01-28
AU2019201259A1 (en) 2019-03-14
UY35441A (es) 2014-10-31
KR20150130492A (ko) 2015-11-23
SG11201506413PA (en) 2015-09-29
MA38487A1 (fr) 2017-12-29
PE20151766A1 (es) 2015-12-11
CR20150545A (es) 2015-12-01
MX2015012843A (es) 2016-08-08
BR112015023404A2 (pt) 2017-07-18
US20180265613A1 (en) 2018-09-20
SG10201707590XA (en) 2017-11-29
TW201521744A (zh) 2015-06-16
DOP2015000221A (es) 2015-12-15
CL2015002624A1 (es) 2016-03-11
TN2015000390A1 (en) 2017-01-03
JP2018135365A (ja) 2018-08-30
JP2016512830A (ja) 2016-05-09

Similar Documents

Publication Publication Date Title
CN102858817B (zh) 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
CA2303447C (en) Cationic polymers as toxin-binding agents
CA2349620C (en) Use of aliphatic polyamines for reducing oxalate
EP2771319B1 (en) Amino acid derivatives functionalized on the n- terminal capable of forming drug incapsulating microspheres
CN1245425A (zh) 聚(二烯丙基胺)基胆汁酸多价螯合体
US6566407B2 (en) Method for reducing oxalate
ES2661079T3 (es) Polímeros de amina para su uso como secuestrantes de ácidos biliares
AU2002257145B2 (en) Method for lowering serum glucose
NZ248193A (en) Crosslinked nitrogen-containing polymers formed by hydrolysis or other treatment of vinyl formamide copolymers; microparticles thereof and pharmaceutical compositions
WO2008042222A2 (en) Amide dendrimer compositions
JP2022037143A (ja) 終末糖化産物（ａｇｅ）前駆体の捕捉剤
JP4465193B2 (ja) リン酸塩輸送インヒビター
JP2009507019A (ja) リン酸塩を除去する方法およびそれに使用される重合体
CN104027816B (zh) 一种可去聚乙二醇化的共装载阿霉素和siRNA载体及其合成方法
JP2017526767A (ja) 主鎖ポリアミン
JP2909500B2 (ja) 水溶性抗高脂質血症剤として有用な官能化側鎖を有するポリアミド
OA17560A (en) Sequestrants of advanced glycation end product (AGE) precursors.
CN116041418A (zh) 羟脯氨酰基-丝氨酸化合物及其制备方法和应用
CN120398706A (zh) 具有组织黏附和ros响应性能的共聚物、载药纳米粒及其制备方法和应用
CN108473676A (zh) 亚砜衍生物配位铂(ii)络合物的高分子偶联物
HK1201525B (en) Amino acid derivatives functionalized on the n-terminal capable of forming drug incapsulating microspheres

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151223